ADC Iza-Bren Ups Survival for Patients with EGFRm NSCLC

For patients with EGFR-mutated non–small lung cancer, a first-in-class bispecific antibody–drug conjugate known as iza-bren increased progression-free and overall survival in newly diagnosed and previously treated disease when used as a monotherapy or in combination with osimertinib. However, the data are preliminary, and questions remain about the long-term safety profile.